Form 4: Lyell Immunopharma Executive Gary K. Lee Reports Stock and Option Awards

Chief Scientific Officer Gary K. Lee reports acquisition of stock and option awards in Lyell Immunopharma, Inc.

Summary

• Gary K. Lee, Chief Scientific Officer of Lyell Immunopharma, Inc., reported changes in beneficial ownership of company stock.
• On February 10, 2025, Lee acquired 112,500 shares of common stock at $0 and was granted options to purchase 506,250 shares of common stock at an exercise price of $0.5535.
• Following these transactions, Lee directly owns 176,696 shares of common stock and options to purchase 506,250 shares.
• The stock options vest beginning August 9, 2025, with a portion vesting quarterly or monthly thereafter, contingent upon continued service.
• Some options are performance-based, vesting upon achievement of specific criteria.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock and option grants, which are common practices. There's no indication of positive or negative news, just routine disclosure.

Positives

• The grant of stock and options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the Chief Scientific Officer.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules suggest an expectation of continued service from the executive.

Industry Context

This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency regarding the alignment of management's interests with shareholders' interests.

Comparison to Industry Standards

• Stock option grants are a common component of executive compensation packages in the biotechnology industry.
• Vesting schedules are generally structured to incentivize long-term performance and retention, similar to practices observed at companies like Amgen, Gilead Sciences, and Regeneron.
• The specific terms of the grant (number of shares, exercise price, vesting schedule) would need to be compared against peer companies to determine if they are within industry norms.

Stakeholder Impact

• The stock and option awards could potentially incentivize the executive to improve company performance, benefiting shareholders.
• The vesting schedule may contribute to employee retention.

Key Dates